Products
Pasritamig Biosimilar Bispecific Antibody (KLK2 × CD3) for Research
Cat No.: GMP-Bios-INN-1329
Anti-KLK2/KLK2A2/hGK-1/hK2 therapeutic antibody (Pre-made Pasritamig biosimilar,Bispecific Mixed Domains ((H-gamma1_L-kappa)_scFvkh-G1(h-CH2-CH3))) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Pasritamig (development code JNJ-78278343) is a bispecific antibody targeting CD3. It is developed by Janssen Research & Development and Zymeworks for prostate cancer. It is in Phase I clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1329-1mg | 1mg | |
| GMP-Bios-INN-1329-10mg | 10mg | |
| GMP-Bios-INN-1329-100mg | 100mg | |
| GMP-Bios-INN-1329-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Pasritamig biosimilar, Bispecific Mixed Domains ((H-gamma1_L-kappa)_scFvkh-G1(h-CH2-CH3)), Anti-KLK2/KLK2A2/hGK-1/hK2;CD3E Antibody: Anti-Kallikrein 2/KLK2/Kallikrein-2/Glandular kallikrein-1 (hGK-1) therapeutic antibody |
| INN Name | Pasritamig |
| Target | KLK2/KLK2A2/hGK-1/hK2;CD3E |
| Format | Bispecific Mixed Domains ((H-gamma1_L-kappa)_scFvkh-G1(h-CH2-CH3)) |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1;G1 |
| VD LC | Kappa;Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2024 |
| Year Recommended | na |
| Companies | Janssen Research & Development;Zymeworks |
| Conditions Approved | na |
| Conditions Active | Prostate cancer |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
